LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.1 1.85

Buy Sell

Overview

Share price change

24h

Current

Min

1.09

Max

1.1

Key metrics
By Trading Economics
Income	-124K -32M
Sales	-372K 1.4M
EPS	-0.27
Profit margin	-2,364.792
Employees	161
EBITDA	-13M -42M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+104.55% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-39M 135M
Previous open	-0.75
Previous close	1.1

News Sentiment

By Acuity

28%

72%

75 / 350 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 mar 2026, 17:19 UTC

Major News Events

Chubb to Assume Risk, Issue Policies for $20 Billion Strait of Hormuz Insurance Facility

20 mar 2026, 16:56 UTC

Major News Events

Week Ahead for FX, Bonds: PMI Data to Show Middle East War's Impact on Sentiment

20 mar 2026, 16:56 UTC

Major News Events

Week Ahead for FX, Bonds: PMI Data to Show Middle -2-

20 mar 2026, 16:45 UTC

Major News Events

The Week in Oil: U.S. Seeks to Ease Concerns Over War But Supply Risks Mount

20 mar 2026, 16:22 UTC

Major News Events

NYMEX Overview: Petroleum Futures Rise, Leaving Most Contracts on Track for Solid Weekly Gains -- OPIS

22 mar 2026, 00:00 UTC

Earnings

Sick of High Gas Prices? EV Deals Are Everywhere Right Now -- WSJ

21 mar 2026, 08:20 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

21 mar 2026, 00:05 UTC

Acquisitions, Mergers, Takeovers

Oil, Long And Short -- Barrons.com

20 mar 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

20 mar 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

20 mar 2026, 19:55 UTC

Market Talk

Major News Events

Brent Crude Closes Out Volatile Week Higher -- Market Talk

20 mar 2026, 19:28 UTC

Market Talk

Major News Events

Natural Gas Falls as Traders Sell Ahead of the Weekend -- Market Talk

20 mar 2026, 19:28 UTC

Acquisitions, Mergers, Takeovers

Ecolab Buys CoolIT Systems for $4.75 Billion. It's All About AI for the Struggling Stock. -- Barrons.com

20 mar 2026, 18:39 UTC

Market Talk

Gold Settles With Largest Weekly Dollar Decline on Record -- Market Talk

20 mar 2026, 18:31 UTC

Acquisitions, Mergers, Takeovers

Honeywell Announces Pricing of Debt Tender Offers >HON

20 mar 2026, 18:19 UTC

Acquisitions, Mergers, Takeovers

Why Mayo and Soap No Longer Mix for Unilever -- Update

20 mar 2026, 18:15 UTC

Market Talk

iMarkets May Be Wrong in Pricing for Canadian Rate Increases -- Market Talk

20 mar 2026, 17:57 UTC

Market Talk

U.S. Oil Rig Count Inches Up -- Market Talk

20 mar 2026, 17:04 UTC

Major News Events

Chubb to Assume Risk, Issue Policies for $20B Strait of Hormuz Insurance Facility

20 mar 2026, 16:20 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

20 mar 2026, 16:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

20 mar 2026, 15:40 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Unilever, McCormick Deal Makes Strategic Sense, But Risk Remains -- Market Talk

20 mar 2026, 15:30 UTC

Earnings

Gemini Space Station's Earnings 'Better Than Feared.' Can They Save the Stock? -- Barrons.com

20 mar 2026, 15:26 UTC

Market Talk

Earnings

Major News Events

Lands' End: War Impacts Weighing on Some European Consumers -- Market Talk

20 mar 2026, 15:26 UTC

Acquisitions, Mergers, Takeovers

Why Mayo and Soap No Longer Mix for Unilever -- WSJ

20 mar 2026, 15:25 UTC

Market Talk

Gilt Selloff Shows Vulnerability of U.K.'s Economy -- Market Talk

20 mar 2026, 15:19 UTC

Market Talk

Major News Events

UBS Raises Oil Price Forecast as Middle East Conflict Escalates -- Market Talk

20 mar 2026, 14:58 UTC

Major News Events

Chevron Jumps Into Top 20 Most Valuable U.S. Companies. The Iran War's Other Big Stock Movers. -- Barrons.com

20 mar 2026, 14:55 UTC

Market Talk

Major News Events

Gold Lower as Speculative Pullback Extends -- Market Talk

20 mar 2026, 14:54 UTC

Acquisitions, Mergers, Takeovers

Ecolab Buys CoolIT Systems for $4.75 Billion. It's All About AI for the Struggling Stock. -- Barrons.com

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

104.55% upside

12 Months Forecast

Average 2.25 USD 104.55%

High 2.5 USD

Low 2 USD

Based on 4 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

75 / 350 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.